Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease.
from Latest Science News -- ScienceDaily http://bit.ly/2UVNFlS
via IFTTT
Wednesday, April 24, 2019
Targeted therapy proves effective against aggressive rare blood cancer
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment